drugset / Trial / NCT02532218
Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The objective of this study is to evaluate the efficacy and safety of ARI-3037MO compared to placebo in reducing low-density lipoprotein cholesterol (LDL-C) levels in subjects with dyslipidemia.
Timeline
- Start
- 2015-08
- Primary completion
- 2016-09
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | ARI-3037MO | Unknown | 3 g | — |